Bionano Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>BG</div>
BNGO -- USA Stock  

USD 8.27  1.53  15.61%

Bionano Genomics Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.30. Current Ratio is expected to rise to 1.76 this year, although the value of Average Assets will most likely fall to about 26.6 M. My story will outline Bionano Genomics. We will cover the possibilities of making Bionano Genomics into a steady grower in February. This post is to show some fundamental factors affecting Bionano Genomics' products and services. I will also disclose how it may impact the investing outlook for the company in February.
Published over two weeks ago
View all stories for Bionano Genomics | View All Stories
Bionano Genomics (NASDAQ:BNGO) continues to rise
About 6.0% of Bionano Genomics shares are held by institutions such as insurance companies. Insiders ownership of Bionano Genomics refers to the amount of Bionano Genomics equity owned by Bionano officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Bionano, including its current ownership diagnostics.

How important is Bionano Genomics's Liquidity

Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bionano Genomics's total debt and its cash.

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

What did Bionano Genomics file with SEC?

The SEC filings are financial statements or other formal documents of Bionano Genomics that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Bionano shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Other Events
View
Other Events
View
Submission of Matters to a Vote of Security Holders
View
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Bionano shareholders may or may not be submitted as SEC does not always require it.

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

Bionano Genomics retains a total of 153.19 Million outstanding shares. Almost 94.0 percent of Bionano Genomics outstanding shares are held by regular investors with 0.06 (percent) owned by insiders and only 5.64 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
94.3%
Institutions
5.64%
Retail Investors94.3
Insiders0.06
Institutions5.64

Can Bionano Genomics build up on the latest rise?

Kurtosis is down to 10.3. It may entail a possible volatility slide. Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.

Our Takeaway on Bionano Genomics Investment

Whereas some firms under the diagnostics & research industry are still a bit expensive, Bionano Genomics may offer a potential longer-term growth to institutional investors. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bionano Genomics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com